JP5665740B2 - デアセチラーゼ阻害剤およびその使用 - Google Patents

デアセチラーゼ阻害剤およびその使用 Download PDF

Info

Publication number
JP5665740B2
JP5665740B2 JP2011520034A JP2011520034A JP5665740B2 JP 5665740 B2 JP5665740 B2 JP 5665740B2 JP 2011520034 A JP2011520034 A JP 2011520034A JP 2011520034 A JP2011520034 A JP 2011520034A JP 5665740 B2 JP5665740 B2 JP 5665740B2
Authority
JP
Japan
Prior art keywords
certain embodiments
moiety
substituted
unsubstituted
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011520034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529048A (ja
JP2011529048A5 (https=
Inventor
ウェイピン タン，
ウェイピン タン，
ジェームズ エリオット ブラッドナー，
ジェームズ エリオット ブラッドナー，
スチュアート エル． シュレイバー，
スチュアート エル． シュレイバー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2011529048A publication Critical patent/JP2011529048A/ja
Publication of JP2011529048A5 publication Critical patent/JP2011529048A5/ja
Application granted granted Critical
Publication of JP5665740B2 publication Critical patent/JP5665740B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2011520034A 2008-07-23 2009-07-22 デアセチラーゼ阻害剤およびその使用 Expired - Fee Related JP5665740B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8289908P 2008-07-23 2008-07-23
US61/082,899 2008-07-23
PCT/US2009/004235 WO2010011296A2 (en) 2008-07-23 2009-07-22 Deacetylase inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014043515A Division JP2014101380A (ja) 2008-07-23 2014-03-06 デアセチラーゼ阻害剤およびその使用

Publications (3)

Publication Number Publication Date
JP2011529048A JP2011529048A (ja) 2011-12-01
JP2011529048A5 JP2011529048A5 (https=) 2012-09-06
JP5665740B2 true JP5665740B2 (ja) 2015-02-04

Family

ID=41570773

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011520034A Expired - Fee Related JP5665740B2 (ja) 2008-07-23 2009-07-22 デアセチラーゼ阻害剤およびその使用
JP2014043515A Pending JP2014101380A (ja) 2008-07-23 2014-03-06 デアセチラーゼ阻害剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014043515A Pending JP2014101380A (ja) 2008-07-23 2014-03-06 デアセチラーゼ阻害剤およびその使用

Country Status (10)

Country Link
US (2) US8440716B2 (https=)
EP (1) EP2321264B1 (https=)
JP (2) JP5665740B2 (https=)
KR (1) KR101708946B1 (https=)
CN (1) CN102164888B (https=)
AU (1) AU2009274549B2 (https=)
CA (1) CA2731730C (https=)
IL (1) IL210804A (https=)
RU (1) RU2515611C2 (https=)
WO (1) WO2010011296A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) * 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
US8304451B2 (en) * 2006-05-03 2012-11-06 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
AU2009274549B2 (en) 2008-07-23 2014-05-01 Dana-Farber Cancer Institute, Inc. Deacetylase inhibitors and uses thereof
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
PH12012501492B1 (en) 2010-01-22 2020-01-24 Acetylon Pharmaceuticals Inc Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
NZ610225A (en) 2010-11-16 2015-08-28 Acetylon Pharmaceuticals Inc Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
GB201110546D0 (en) * 2011-06-22 2011-08-03 Imp Innovations Ltd Compositions
EP2872125A4 (en) * 2012-07-10 2016-02-24 Dana Farber Cancer Inst Inc ANTIPROLIFERATIVE COMPOUNDS AND USES THEREOF
WO2015054099A1 (en) 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors
US9278963B2 (en) 2013-10-10 2016-03-08 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
WO2015084905A1 (en) 2013-12-03 2015-06-11 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and immunomodulatory drugs
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
JP6952602B2 (ja) 2014-07-07 2021-10-20 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストンデアセチラーゼ阻害剤による白血病の治療
US9937174B2 (en) 2014-12-05 2018-04-10 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
JP6873053B2 (ja) 2015-06-08 2021-05-19 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． タンパク質脱アセチル化阻害剤の製造方法
EP3303306B1 (en) 2015-06-08 2020-02-12 Acetylon Pharmaceuticals, Inc. Crystalline forms of a histone deacetylase inhibitor
PL3328843T3 (pl) * 2015-07-27 2023-02-27 Chong Kun Dang Pharmaceutical Corp. Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca
CN108026056B (zh) 2015-07-27 2021-08-03 株式会社钟根堂 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑酰胺衍生物化合物及其药物组合物
RU2695227C9 (ru) * 2015-07-27 2020-03-04 Чонг Кун Данг Фармасьютикал Корп. Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
JP6491393B2 (ja) 2015-08-04 2019-03-27 チョン クン ダン ファーマシューティカル コーポレーション ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾール誘導体化合物及びこれを含有する薬剤学的組成物
JP6697074B2 (ja) 2015-10-12 2020-05-20 チョン クン ダン ファーマシューティカル コーポレーション ヒストン脱アセチル化酵素６阻害剤としてのオキサジアゾールアミン誘導体化合物及びこれを含有する薬剤学的組成物
US11813261B2 (en) 2016-04-19 2023-11-14 Acetylon Pharmaceuticals, Inc. HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia
RU2768826C2 (ru) * 2016-06-07 2022-03-24 Дермавант Саенсиз Гмбх Составы на основе ингибиторов pde-4 для местного применения и способы их применения
ES2929032T3 (es) 2016-08-08 2022-11-24 Acetylon Pharmaceuticals Inc Combinaciones farmacéuticas de inhibidores de histona desacetilasa 6 y anticuerpos inhibidores de CD20 y usos de los mismos
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
MY207444A (en) 2019-05-31 2025-02-27 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX2022007376A (es) 2019-12-20 2022-09-02 Tenaya Therapeutics Inc Fluoroalqull-oxadiazoles y sus usos.
IL307883A (en) 2021-04-23 2023-12-01 Tenaya Therapeutics Inc HDAC6 inhibitors for use in the treatment of dilated myocardial disease
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef
CN115192714B (zh) * 2022-07-08 2024-09-17 沈阳药科大学 Hdac6抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7014A (en) * 1850-01-15 Folding bedstead
US4009A (en) * 1845-04-22 Sawmill-carriage
HU165117B (https=) 1971-08-12 1974-06-28
US4160866A (en) 1976-04-30 1979-07-10 Imperial Chemical Industries Limited Carbamates
DE3242252A1 (de) * 1982-11-15 1984-05-17 Bayer Ag, 5090 Leverkusen Heterocyclisch substituierte hydroxyalkyl-azolyl-derivate
NL194579C (nl) 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4608390A (en) 1985-04-26 1986-08-26 Abbott Laboratories Lipoxygenase inhibiting compounds
US4833080A (en) * 1985-12-12 1989-05-23 President And Fellows Of Harvard College Regulation of eucaryotic gene expression
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
US4861798A (en) 1986-12-29 1989-08-29 Bristol-Myers Company Lipoxygenase inhibitory compounds
US4820828A (en) * 1987-03-04 1989-04-11 Ortho Pharmaceutical Corporation Cinnamohydroxamic acids
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
ES2008962A6 (es) 1987-12-17 1989-08-16 Marga Investigacion Proceso para la preparacion de nuevos compuestos de 2-guanidinotiazol
EP0323590A3 (en) 1987-12-24 1990-05-02 Ono Pharmaceutical Co., Ltd. Carbazoyl derivatives
JPH01224381A (ja) 1988-03-04 1989-09-07 Japan Tobacco Inc トリコスタチン酸、トリコスタチンａの新規な合成中間体、及びトリコスタチン酸、トリコスタチンａの製造方法。
EP0347381B1 (de) * 1988-06-13 1992-02-12 Ciba-Geigy Ag Ungesättigte beta-Ketoesteracetale und ihre Anwendungen
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
WO1991000257A1 (en) 1989-06-30 1991-01-10 The Trustees Of Columbia University In The City Of New York Novel potent inducers of terminal differentiation and methods of use thereof
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
WO1991007087A1 (en) 1989-11-13 1991-05-30 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
FR2659648B1 (fr) 1990-03-13 1993-02-12 Michelin Rech Tech Procede pour preparer un produit aromatique alkyle avec une zeolithe d'alkylation et une zeolithe de dealkylation.
JPH0422948A (ja) 1990-05-18 1992-01-27 Fuji Photo Film Co Ltd 写真用処理組成物及び処理方法
EP0720049B1 (en) 1990-05-09 1999-08-04 Fuji Photo Film Co., Ltd. Photographic processing composition and processing method using the same
US5045538A (en) * 1990-06-28 1991-09-03 The Research Foundation Of State University Of New York Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
GB9026114D0 (en) * 1990-11-30 1991-01-16 Norsk Hydro As New compounds
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
EP0501919A1 (de) * 1991-03-01 1992-09-02 Ciba-Geigy Ag Strahlungsempfindliche Zusammensetzungen auf der Basis von Polyphenolen und Acetalen
WO1992015694A1 (en) 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
US5225173A (en) * 1991-06-12 1993-07-06 Idaho Research Foundation, Inc. Methods and devices for the separation of radioactive rare earth metal isotopes from their alkaline earth metal precursors
AU2677592A (en) 1991-09-13 1993-04-27 New England Deaconess Hospital Erythropoietin potentiating agents and methods for their use
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5239113A (en) 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
CA2124087C (en) 1991-11-22 2002-10-01 James L. Winkler Combinatorial strategies for polymer synthesis
EP0570594B1 (en) 1991-12-10 1997-07-30 Shionogi & Co., Ltd. Hydroxamic acid derivative based on aromatic sulfonamide
US5359115A (en) * 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1993019778A1 (en) 1992-04-07 1993-10-14 The Scripps Research Institute Method for inducing tolerance to an antigen using butyrate
JP3356304B2 (ja) 1992-06-16 2002-12-16 財団法人生産開発科学研究所 抗炎、抗潰瘍剤
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
KR100310939B1 (ko) 1992-10-01 2002-06-20 추후제출 태그로암호화한복합조합화학라이브러리
WO1994010300A1 (en) 1992-10-30 1994-05-11 The General Hospital Corporation Interaction trap system for isolating novel proteins
US5480971A (en) * 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US5440016A (en) * 1993-06-18 1995-08-08 Torrey Pines Institute For Molecular Studies Peptides of the formula (KFmoc) ZZZ and their uses
US20030203976A1 (en) * 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5362899A (en) * 1993-09-09 1994-11-08 Affymax Technologies, N.V. Chiral synthesis of alpha-aminophosponic acids
US5659016A (en) 1994-09-22 1997-08-19 Cancer Institute RPDL protein and DNA encoding the same
US6231600B1 (en) * 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
JP3330781B2 (ja) 1995-05-22 2002-09-30 三菱エンジニアリングプラスチックス株式会社 ポリカーボネート樹脂組成物
WO1997011366A1 (en) 1995-09-20 1997-03-27 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
JPH09124918A (ja) 1995-10-30 1997-05-13 Mitsubishi Eng Plast Kk ポリカーボネート樹脂組成物
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6273912B1 (en) * 1996-02-28 2001-08-14 Impra, Inc. Flanged graft for end-to-side anastomosis
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6068987A (en) * 1996-09-20 2000-05-30 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
WO1998016830A2 (en) 1996-10-16 1998-04-23 The President And Fellows Of Harvard College Droplet assay system
ZA9710342B (en) * 1996-11-25 1998-06-10 Alza Corp Directional drug delivery stent and method of use.
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
NZ500590A (en) * 1997-04-22 2001-11-30 Cocensys Inc Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6190619B1 (en) * 1997-06-11 2001-02-20 Argonaut Technologies, Inc. Systems and methods for parallel synthesis of compounds
US5891507A (en) * 1997-07-28 1999-04-06 Iowa-India Investments Company Limited Process for coating a surface of a metallic stent
US6195612B1 (en) * 1998-01-05 2001-02-27 Tama L. Pack-Harris Pharmacy benefit management system and method of using same
US6503708B1 (en) 1998-01-26 2003-01-07 Incyte Genomics, Inc. Microtubule-associated protein
US6428960B1 (en) * 1998-03-04 2002-08-06 Onyx Pharmaceuticals, Inc. Selection method for producing recombinant baculovirus
US6037361A (en) 1998-03-09 2000-03-14 Warner-Lambert Company Fluorinated butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US6153252A (en) * 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US6248127B1 (en) * 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device
DE19846008A1 (de) 1998-10-06 2000-04-13 Bayer Ag Phenylessigsäure-heterocyclylamide
TR200101663T2 (tr) 1998-12-10 2001-11-21 F.Hoffmann-La Roche Ag Pro-kollajen c-proteinaz inhibitörleri
AU3118200A (en) 1998-12-14 2000-07-03 Merck & Co., Inc. Hiv integrase inhibitors
CA2355075C (en) 1998-12-16 2009-12-08 Aventis Pharma Limited Heteroaryl-cyclic acetals
AR035313A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
EP1152936B1 (de) * 1999-02-01 2003-12-03 Continental Teves AG & Co. oHG Drucksteuergerät
US6258121B1 (en) * 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6203551B1 (en) * 1999-10-04 2001-03-20 Advanced Cardiovascular Systems, Inc. Chamber for applying therapeutic substances to an implant device
EP1748046A3 (en) * 1999-11-23 2007-08-22 Methylgene, Inc. Inhibitors of histone deacetylase
US6251136B1 (en) * 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US6797820B2 (en) 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
US20030129724A1 (en) * 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
EP1335898B1 (en) * 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US7314953B2 (en) 2001-03-27 2008-01-01 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
AR035455A1 (es) * 2001-04-23 2004-05-26 Hoffmann La Roche Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
US7244853B2 (en) * 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
WO2002089782A2 (en) 2001-05-09 2002-11-14 President And Fellows Of Harvard College Dioxanes and uses thereof
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
JP2003221398A (ja) 2001-11-22 2003-08-05 Japan Science & Technology Corp 蛍光又は発色基質を用いたヒストンデアセチラーゼ活性測定法
US6517889B1 (en) * 2001-11-26 2003-02-11 Swaminathan Jayaraman Process for coating a surface of a stent
AU2002362030A1 (en) 2001-11-27 2003-06-10 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
CN101259120B (zh) * 2002-03-04 2012-07-04 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途
NO20032183L (no) 2002-05-15 2003-11-17 Schering Ag Histon-deacetylase-inhibitor og anvendelse derav
JP2004043446A (ja) 2002-05-15 2004-02-12 Schering Ag ヒストンデアセチラーゼ抑制剤及びその使用
WO2003101481A1 (en) * 2002-06-03 2003-12-11 Als Therapy Development Foundation Treatment of neurodegenerative diseases using proteasome modulators
TW200401638A (en) 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
TW200420573A (en) 2002-09-26 2004-10-16 Rib X Pharmaceuticals Inc Bifunctional heterocyclic compounds and methods of making and using same
AU2003273701A1 (en) * 2002-10-17 2004-05-04 Methylgene Inc. Inhibitors of histone deacetylase
EP1565193B1 (en) * 2002-11-06 2013-04-24 Dana-Farber Cancer Institute, Inc. Compositions for treating cancer using proteasome inhibitor PS-341
KR101076018B1 (ko) 2003-01-08 2011-10-21 유니버시티 오브 워싱톤 항균제
JP4790594B2 (ja) * 2003-02-25 2011-10-12 トポターゲット ユーケー リミテッド Ｈｄａｃインヒビターとしての、二環式ヘテロアリール基を含むヒドロキサム酸化合物
TW200503022A (en) * 2003-03-17 2005-01-16 Tdk Corp Capacitor element, solid electrolytic capacitor, process for producing the same, and combination of capacitor elements
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
WO2005007091A2 (en) 2003-07-07 2005-01-27 Georgetown University Histone deacetylase inhibitors and methods of use thereof
US7842835B2 (en) * 2003-07-07 2010-11-30 Georgetown University Histone deacetylase inhibitors and methods of use thereof
WO2005012247A1 (en) 2003-07-30 2005-02-10 Hôpital Sainte-Justine Compounds and methods for the rapid quantitative analysis of proteins and polypeptides
SI1663194T1 (sl) 2003-08-26 2010-08-31 Merck Hdac Res Llc Uporaba SAHA za zdravljenje mezotelioma
DE10346913A1 (de) * 2003-10-09 2005-05-04 Merck Patent Gmbh Acylhydrazonderivate
EP1541549A1 (en) 2003-12-12 2005-06-15 Exonhit Therapeutics S.A. Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
JP4989976B2 (ja) 2004-02-13 2012-08-01 プレジデント アンド フェロウズ オブ ハーバード カレッジ 翻訳開始阻害剤としての３−３−二置換オキシインドール
CA2590334A1 (en) 2004-12-03 2006-06-08 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
SG157365A1 (en) 2004-12-03 2009-12-29 Dana Farber Cancer Inst Inc Compositions and methods for treating neoplastic diseases
US8999289B2 (en) * 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
US7438916B2 (en) 2005-10-14 2008-10-21 Virginia Tech Intellectual Properties, Inc. Therapeutic target for protozoal diseases
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
WO2007095584A2 (en) * 2006-02-14 2007-08-23 The President And Fellows Of Harvard College Histone Deacetylase Inhibitors
EP2007383A4 (en) 2006-03-22 2010-09-15 Univ California HEMMER OF PROTEIN PRENYL TRANSFERASES
US8304451B2 (en) * 2006-05-03 2012-11-06 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
CN105481788A (zh) 2006-10-28 2016-04-13 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
US8088951B2 (en) * 2006-11-30 2012-01-03 Massachusetts Institute Of Technology Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
JP2011500783A (ja) 2007-10-22 2011-01-06 オーキッド リサーチ ラボラトリーズ リミテッド ヒストンデアセチラーゼ阻害剤
EP2060565A1 (en) 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
AU2009274549B2 (en) 2008-07-23 2014-05-01 Dana-Farber Cancer Institute, Inc. Deacetylase inhibitors and uses thereof
WO2010019924A1 (en) 2008-08-15 2010-02-18 Burnham Institute For Medical Research Composition and methods for the design and development of metallo-enzyme inhibitors
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
US20130040998A1 (en) 2010-01-08 2013-02-14 Dana-Farber Cancer Institute, Inc. Fluorinated hdac inhibitors and uses thereof

Also Published As

Publication number Publication date
WO2010011296A2 (en) 2010-01-28
JP2011529048A (ja) 2011-12-01
JP2014101380A (ja) 2014-06-05
IL210804A (en) 2015-06-30
KR20110046484A (ko) 2011-05-04
US20110172303A1 (en) 2011-07-14
AU2009274549A1 (en) 2010-01-28
WO2010011296A3 (en) 2010-04-22
KR101708946B1 (ko) 2017-02-21
EP2321264A4 (en) 2011-09-21
CA2731730A1 (en) 2010-01-28
IL210804A0 (en) 2011-04-28
US20130331455A1 (en) 2013-12-12
RU2011106799A (ru) 2012-08-27
EP2321264A2 (en) 2011-05-18
US8440716B2 (en) 2013-05-14
CN102164888B (zh) 2015-06-03
CA2731730C (en) 2017-06-13
CN102164888A (zh) 2011-08-24
RU2515611C2 (ru) 2014-05-20
HK1161583A1 (en) 2012-07-27
AU2009274549B2 (en) 2014-05-01
US9434686B2 (en) 2016-09-06
EP2321264B1 (en) 2016-05-04

Similar Documents

Publication Publication Date Title
JP5665740B2 (ja) デアセチラーゼ阻害剤およびその使用
JP5497431B2 (ja) ヒストンデアセチラーゼおよびチューブリンデアセチラーゼ阻害剤
EP1991247B1 (en) Bifunctional histone deacetylase inhibitors
JP5409015B2 (ja) ヒストンデアセチラーゼ阻害剤
US20140107166A1 (en) Histone deacetylase inhibitors and methods of use thereof
HK1125580B (en) Bifunctional histone deacetylase inhibitors
HK1161583B (en) Deacetylase inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120720

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140708

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141209

R150 Certificate of patent or registration of utility model

Ref document number: 5665740

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees